, , , , , , ,

Corin reports positive long-term trial data for Cormet.

Posted on 10/05/2012 in Medical Company Product News

Corin’s hip resurfacing device Cormet has had its long-term efficacy underlined by a new follow-up study conducted over an 11-year period.

The report was published in a recent issue of the Journal of Arthroplasty and demonstrates a 93 percent survivorship at 11 years for all patient groups and reasons for revision.

Meanwhile, a 98 percent survivorship at seven years after the learning curve was also observed, meaning the device offers superior performance to comparable devices, as well as providing advantages over Birmingham hip resurfacing techniques.

Other findings from the study showed that any femoral neck fractures occurred before the six-month follow-up, while revisions due to adverse reactions to wear debris was a rare clinical problem.

Corin said: “This demonstrates the effectiveness of Cormet and continues to differentiate us from other devices.”

According to the company’s most recent financial report, Corin saw a 12 percent year-on-year increase in sales during 2011, bringing its revenue total up to 47.9 million pounds.ADNFCR-8000103-ID-801360340-ADNFCR